9-month-old Alzheimer's drug Leqembi faces slow adoption due to doctors' skepticism over efficacy, cost, and risks.
9 months into the U.S. launch of Leqembi, the first Alzheimer's drug proven to slow progression, faces an unexpected barrier to widespread use: doctors' skepticism over its efficacy. While experts anticipated challenges due to Leqembi's requirements, including additional tests, infusions, and brain scans, its adoption has been slow since FDA approval. Concerns about efficacy, cost, and risks have contributed to lower prescription rates.
April 28, 2024
13 Articles